ipratropium bromide + salbutamol: clinical use

Prescribing considerations

• Confirm that both bronchodilator components are clinically required for COPD bronchospasm.
• Initiation and administration should be medically supervised; home nebuliser use requires clinical review and patient competence.
• Avoid mist entering the eyes and review mask fit, particularly in patients at risk of narrow-angle glaucoma.
• There is no product-specific clinical experience in children younger than 12 years.

Contraindications and cautions

• Hypertrophic obstructive cardiomyopathy
• Tachyarrhythmia
• Hypersensitivity to ipratropium, salbutamol, atropine or atropine derivatives

Monitoring

• Clinical response and nebuliser technique
• Heart rate, rhythm and cardiovascular symptoms in susceptible patients
• Serum potassium when severe airway obstruction, interacting treatment or hypoxia increases hypokalaemia risk
• Blood glucose where diabetes is insufficiently controlled
• Lactate and acid-base status with unexplained persistent tachypnoea during intensive nebulised short-acting beta2-agonist treatment
• Ocular symptoms and urinary retention in predisposed patients

Clinical pharmacology

Ipratropium produces mainly local antimuscarinic bronchodilation, while salbutamol relaxes airway smooth muscle through beta2-receptor activation. Their additive effect reflects complementary local receptor activity in the lungs.

Formulation and product differences

• The selected product is a clear, preservative-free nebuliser solution in single-use polyethylene vials.
• Opened, partly used or damaged vials must be discarded.
• It is for inhalation through a suitable nebuliser or intermittent positive-pressure ventilator, not oral or parenteral administration.
• Keep in the outer carton, below 25°C and protected from light; do not freeze or use discoloured solution.